'DNA bungle' haunts German police
By BBC,
BBC News
| 03. 28. 2009
Police in Germany have admitted that a woman they have been hunting for more than 15 years never in fact existed.
Dubbed the "phantom of Heilbronn", the woman was described by police as the country's most dangerous woman.
Investigators had connected her to six murders and an unsolved death based on DNA traces found at the scene.
Police now acknowledge swabs used to collect DNA samples were contaminated by an innocent woman working in a factory in Bavaria.
'Serial killer'
Police suspected the unnamed woman of being a serial killer who over 16 years carried out a string of six murders, including strangling a pensioner.
She was alternatively called the "woman without a face" and the "phantom of Heilbronn" after the city in southern Germany where she allegedly killed a policewoman.
Police suspicions were based on traces of identical female DNA they found at 40 crime scenes across southern Germany and Austria.
After finding her DNA at the scene of the murder of a 22-year policewoman from Heilbronn in 2007, police offered a 300,000 euro reward for information leading to...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...